Fig. 3

Higher AdV viral load and burden were associated with a significantly greater risk of all-cause mortality in multivariable models. AdV AAUC_0-16, log₁₀ of the time-averaged area under the AdV viremia curve over the 16 weeks following first AdV viremia ≥ 1000 copies/ml; Peak AdV viremia, peak log₁₀ AdV viremia over the 16 weeks following first AdV viremia ≥ 1000 copies/ml; Days with AdV viremia < 1000 copies/ml, number of days where AdV viremia was <1000 copies/ml over the 16 weeks following first AdV viremia ≥ 1000 copies/ml; Days with undetectable AdV viremia, number of days where AdV viremia was undetectable over the 16 weeks following first AdV viremia ≥ 1000 copies/ml; 2-week change in AdV viremia, change in log₁₀ AdV viremia in the first 2 weeks from first AdV viremia ≥ 1000 copies/ml. Q, quartile; ref, reference group. Note: Factors with P ≤ 0.20 in the univariate analysis were brought forward into the multivariable models, followed by a backward selection to keep the factors with P ≤ 0.10 in the final models. Lymphocyte count, gender, and renal replacement therapy were also significant (P < 0.05) prognostic factors in each of the final multivariable models